The opening of a new mRNA manufacturing facility by Trilink Biotechnologies, a Maravai LifeSciences company, is likely to have a positive impact on MRVI's stock in the short term. This expansion enhances the company's capabilities in the rapidly growing field of mRNA technology, which is crucial for vaccine and therapeutic development. The increased capacity for mRNA production could lead to new contracts and partnerships, further solidifying Maravai LifeSciences' position in the biotechnology industry.